Natural and induced humoral responses to MUC1

Cancers

Volumn 3, Issue 3, 2011, Pages 3073-3103

  von Mensdorff Pouilly, Silvia ^a   Moreno, Maria ^a   Verheijen, René H M ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Anti MUC1 antibodies; Cancer; Immunotherapy; MUC1 based vaccines; Natural humoral response

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPEPTIDE; HMFG1; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; MUCIN 1; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; BREAST CANCER; BREAST CARCINOMA; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CARBOHYDRATE SYNTHESIS; CELL INTERACTION; CELL MEMBRANE DEPOLARIZATION; CYTOTOXIC T LYMPHOCYTE; DRUG DOSE INCREASE; ENDOMETRIUM CANCER; EPITOPE MAPPING; HUMAN; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LUNG CARCINOMA; LYMPH NODE METASTASIS; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; REVIEW; STOMACH CANCER; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT;

EID: 80053179838     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3033073     Document Type: Review

References (166)

1. Hattrup, C.L.; Gendler, S.J. Structure and function of the cell surface (tethered) mucins. Annu. Rev. Physiol. 2008, 70, 431-457.
2. Kufe, D.W. Mucins in cancer: Function, prognosis and therapy. Nat. Rev. Cancer 2009, 9, 874-885.
3. Jonckheere, N.; Van Seuningen, I. The membrane-bound mucins: From cell signaling to transcriptional regulation and expression in epithelial cancers. Biochimie 2010, 92, 1-11.
4. Taylor-Papadimitriou, J.; Peterson, J.A.; Arklie, J.; Burchell, J.; Ceriani, R.L.; Bodmer, W.F. Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: Production and reaction with cells in culture. Int. J. Cancer 1981, 28, 17-21.
5. Price, M.R.; Rye, P.D.; Finn, O.J.; Hilgers, J. Summary report on the ISOBM TD-4 workshop: Analysis of 56 monoclonal antbodies against the MUC1 mucin. Tumor Biol. 1998, 19, S1-S20.
6. Zotter, S.; Hageman, P.C.; Lossnitzer, A.; Mooi, W.J.; Hilgers, J. Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev. 1988, 11-12, 55-101.
7. Girling, A.; Bartkova, J.; Burchell, J.; Gendler, S.; Gillett, C.; Taylor-Papadimitriou, J. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int. J. Cancer 1989, 43, 1072-1076.
8. Van Elssen, C.H.; Frings, P.W.; Bot, F.J.; Van de Vijver, K.K.; Huls, M.B.; Meek, B.; Hupperets, P.; Germeraad, W.T.; Bos, G.M. Expression of aberrantly glycosylated Mucin-1 in ovarian cancer. Histopathology 2010, 57, 597-606.
9. Dent, G.A.; Civalier, C.J.; Brecher, M.E.; Bentley, S.A. MUC1 expression in hematopoietic tissues. Am. J. Clin. Pathol. 1999, 111, 741-747.
10. Brossart, P.; Schneider, A.; Dill, P.; Schammann, T.; Grünebach, F.; Wirths, S.; Kanz, L.; Bühring, H.J.; Brugger, W. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res. 2001, 61, 6846-6850.
11. ten Berge, R.L.; Snijdewint F.G.; von Mensdorff-Pouilly, S.; Poort-Keesom, R.J.; Oudejans, J.J.; Meijer, J.W.; Willemze, R.; Hilgers, J.; Meijer, C.J. MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form. J. Clin. Pathol. 2001, 54, 933-939.
12. Cloosen, S.; Gratama, J.; van Leeuwen, E.B.; Senden-Gijsbers, B.L.; Oving, E.B.; von Mensdorff-Pouilly, S.; Tarp, M.A.; Mandel, U.; Clausen, H.; Germeraad, W.T. et al. Cancer specific Mucin-1 glycoforms are expressed on multiple myeloma. Br. J. Haematol. 2006, 135, 513-516.
13. McGuckin, M.A.; Walsh, M.D.; Hohn, B.G.; Ward, B.G.; Wright, R.G. Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum. Pathol. 1995, 26, 432-439.
14. Dong, Y.; Walsh, M.D.; Cummings, M.C.; Wright, R.G.; Khoo, S.K.; Parson, P.G.; McGuckin, M.A. Expression of MUC1 and MUC2 mucins in epithelial ovarian tumors. J. Pathol. 1997, 183, 311-317.
15. Fujita, K.; Denda, K.; Yamamoyo, M.; Matsumoto, T.; Fujime, M.; Irimura, T. Expression of MUC1 mucins inversely correlated with postsurgical survival of renal cell carcinoma patients. Br. J. Cancer 1999, 80, 301-308.
16. Rahn, J.J.; Dabbagh, L.; Pasdar, M.; Hugh, J.C. The importance of MUC1 cellular localization in patients with breast carcinoma: An immunohistologic study of 71 patients and review of the literature. Cancer 2001, 91, 1973-1982.
17. Hinoda, Y.; Ikematsu, Y.; Horinochi, M.; Sato, S.; Yamamoto, K.; Nakano, T.; Fukui, M.; Suehiro, Y.; Hamanaka, Y.; Nishikawa, Y. et al. Increased expression of MUC1 in advanced pancreatic cancer. J. Gastroenterol. 2003, 38, 1162-1166.
18. Bon, G.G.; von Mensdorff-Pouilly, S.; Kenemans, P.; van Kamp, G.J.; Verstraeten, R.A.; Hilgers, J.; Meijer, S.; Vermorken, J.B. Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays. Clin. Chem. 1997, 43, 585-93.
19. Duffy, M.J.; Evoy, D.; McDermott, E.W. CA 15-3: Uses and limitation as a biomarker for breast cancer. Clin. Chim. Acta 2010, 411, 1869-1874.
20. Gendler, S.J.; Taylor-Papadimitriou, J.; Duhig, T.; Rothbard, J.; Burchell, J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J. Biol. Chem. 1988, 263, 12820-12823.
21. Swallow, D.M.; Gendler, S.; Griffiths, B.; Corney, G.; Taylor-Papadimitriou, J.; Bramwell, M.E. The human tumour-associated epithelial mucins are coded by an expressed hypervariable gene locus PUM. Nature 1987, 328, 82-84.
22. Gendler, S.J.; Lancaster, C.A.; Taylor-Papadimitriou, J.; Duhig, T.; Peat, N.; Burchell, J.; Pemberton, L.; Lalani, E.N.; Wilson, D. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J. Biol. Chem. 1990, 265, 15286-15293.
23. Lloyd, K.O.; Burchell, J.; Kudryashov, V.; Yin, B.; Taylor-Papadimitriou, J. Comparison of O-linked carbohydrate chains in MUC1-mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells. J. Biol. Chem. 1996, 271, 33325-33334.
24. Engelmann, K.; Baldus, S.E.; Hanisch, F.G. Identification and topology of variant sequences within individual repeat domains of the human epithelial tumor mucin MUC1. J. Biol. Chem. 2001, 276, 27764-27769.
25. Fowler, J.C.; Teixeira, A.S.; Vinall, L.E.; Swallow, D.M. Hyper variability of the membrane associated mucin and cancer marker MUC1. Hum. Genet. 2003, 113, 473-479.
26. Hanisch, F.G.; Ninkovic, T. Immunology of O-glycosylated proteins: Approaches to the design of a MUC1 glycopeptide-based tumor vaccine. Curr. Protein Pept. Sci. 2006, 7, 307-315.
27. Karsten, U.; von Mensdorff-Pouilly, S.; Goletz, S. What makes MUC1 a tumor antigen? Tumor Biol. 2005, 26, 217-220.
28. Zhang, S.; Zhang, H.S.; Cordon-Cardo, C.; Reuter, V.E.; Singhal, A.K.; Lloyd, K.O.; Livingston, P.O. Selection of tumor antigens as targets for immune attack using immunehistochemistry: II. Blood group-related antigens. Int. J. Cancer 1997, 73, 50-56.
29. Springer, G.F. Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J. Mol. Med. 1997, 75, 594-602.
30. Livingston, P.O.; Ragupathi, G. Cancer vaccines targeting carbohydrate antigens. Hum. Vaccin 2006, 2, 137-143.
31. Cazet, A.; Julien, S.; Bobowski, M.; Burchell, J.; Delannoy, P. Tumour-associated carbohydrate antigens in breast cancer. Breast Cancer Res. 2010, 12, 204.
32. Aplin, J.D.; Hey, N.A. MUC1, endometrium and embryo implantation. Biochem. Soc. Trans. 1995, 23, 826-831.
33. Hilkens, J.; Wesseling, J.; Vos, H.L.; Storm, J.; Boer, B.; Van Der Valk, S.W.; Maas, M.C.E. Involvement of the cell-surface bound mucin, episialin/MUC1, in progression of human carcinomas. Biochem. Soc. Trans. 1995, 23, 822-826.
34. Agrawal, B.; Longenecker, B.M. MUC1 mucin-mediated regulation of human T cells. Int. Immunol. 2005, 17, 391-399.
35. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674.
36. Agrawal, B.; Krantz, M.J.; Reddish, M.A.; Longenecker, B.M. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat. Med. 1998, 4, 43-49.
37. Chan, A.K.; Lockhart, D.C.; Von Bernstorff, W.; Spanjaard, R.A.; Joo, H.-G.; Eberlein, T.J.; Goedegebuure, P.S. Soluble MUC1 secreted by human epithelial cancer cells mediate immune suppression by blocking T-cell activation. Int. J. Cancer 1999, 82, 721-726.
38. Singh, P.K.; Hollingsworth, M.A. Cell surface-associated mucins in signal transduction. Trends Cell Biol. 2006, 16, 467-76.
39. Kufe, D. Oncogenic function of the MUC1 receptor subunit in gene regulation. Oncogene 2010, 29, 5663-5666.
40. Behrens, M.E.; Grandgenett, P.M.; Bailey, J.M.; Singh, P.K.; Yi, C-H.; Yu, F. Hollingsworth, M.A. The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF. Oncogene 2010, 29, 5667-5677.
41. Khodarev, N.N.; Pitroda, S.P.; Beckett, M.A.; MacDermed, D.M.; Huang, L.; Kufe, D.W.; Weichselbaum, R.R. MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. Cancer Res. 2009, 69, 2833-2837.
42. von Mensdorff-Pouilly, S.; Snijdewint, F.G.; Verstraeten, A.A.; Verheijen, R.H.; Kenemans, P. Human MUC1 mucin: A multifaceted glycoprotein. Int. J. Biol. Markers 2000, 15, 343-556.
43. Bon, G.G.; Kenemans, P.; Verstraeten, A.A.; Go, S.; Philipi, P.A.; van Kamp, G.J.; van Geijn, H.P.; van Vugt, J.M. Maternal serum Ca125 and Ca15-3 antigen levels in normal and pathological pregnancy. Fetal. Diagn. Ther. 2001, 16, 166-172.
44. McGuckin, M.A.; Devine, P.L.; Ramm, L.E.; Ward, B.G. Factors effecting the measurement of tumor-associated MUC1 mucins in serum. Tumor Biol. 1994, 15, 33-44.
45. Agrawal, B.; Reddish, M.A. Does pregnancy immunize against breast cancer? Cancer Res. 1995, 55, 2257-2261.
46. Croce, M.V.; Isla-Larrain, M.T.; Capafons, A.; Price, M.R.; Segal-Eiras, A. Humoral immune response induced by the protein core of MUC1 Mucin in pregnant and healthy women. Breast Cancer Res. Treat. 2001, 69, 1-11.
47. Vinall, L.E.; King, M.; Green, C.A.; Daniels, G.; Hilkens, J.; Sarner, M.; Swallow D.M. Altered expression and allelic association of the hypervariable membrane mucin MUC1 in Helicobacter pylori gastritis. Gastroenterology 2002, 123, 41-49.
48. Mommers, E.C.; Leonhart, A.M.; von Mensdorff-Pouilly, S.; Schol, D.J.; Hilgers, J.; Meijer, C.J.; Baak, J.P.; van Diest, P.J. Aberrant expression of MUC1 mucin in ductal hyperplasia and ductal carcinoma in situ of the breast. Int. J. Cancer 1999, 84, 466-469.
49. Rughetti, A.; Turchi, V.; Apollonj-Ghetti, C.; Scambia, G.; Panici, P.B.; Roncucci, G.; Mancuso, S.; Frati, L.; Nuti, M. Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res. 1993, 53, 2457-2459.
50. Ioannides, C.G.; Fisk, B.; Jerome, K.R.; Irimura, T.; Wharton, J.T.; Finn, O.J. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J. Immunol. 1993, 151, 3693-3703.
51. Petrarca, C.; Casalino, B.; Von Mensdorff-Pouilly, S.; Rughetti, A.; Rahimi, H.; Scambia, G.; Hilgers, J.; Frati, L.; Nuti, M. Isolation of MUC1-primed B-lymphocytes from tumor draining lymph nodes using immunomagentic beads. Cancer Immunol. Immunother. 1999, 47, 272-277.
52. Croce, M.V.; Price, M.R.; Segal-Eiras, A. Expression of monoclonal-antibody-defined antigens in fractions isolated from human breast carcinomas and patients'serum. Cancer Immunol. Immunother. 1995, 40, 132-137.
53. Gourevitch, M.M.; von Mensdorff-Pouilly, S.; Litvinov, S.V.; Kenemans, P.; van Kamp, G.J.; Verstraeten, A.A.; Hilgers, J. Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. Br. J. Cancer 1995, 72, 934-938.
54. Croce, M.V.; Isla-Larrain, M.T.; Demichelis, S.O.; Gori, J.R.; Price, M.R.; Segal-Eiras, A. Tissue and serum MUC1 mucin detection in breast cancer patients. Breast Cancer Res. Treat. 2003, 81, 195-207.
55. Rabassa, M.E.; Croce, M.V.; Pereyra, A.; Segal-Eiras, A. MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): A multivariate analysis. BMC Cancer 2006, 6, 253.
56. von Mensdorff-Pouilly, S.; Gourevitch, M.M.; Kenemans, P.; Verstraeten, A.A.; Litvinov, S.V.; Van Kamp, G.J.; Meijer, S.; Vermorken, J.; Hilgers, J. Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. Eur. J. Cancer 1996, 32A, 1325-1331.
57. Hinoda, Y.; Nakagawa, N.; Nakamura, H.; Makiguchi, Y.; Itoh, F.; Adachi, M.; Yabana, T.; Imai, K.; Yachi, A. Detection of a circulating antibody against a peptide epitope on a mucin core protein, MUC1, in ulcerative colitis. Immunol. Lett. 1993, 35, 163-168.
58. Takaishi, H.; Ohara, S.; Hotta, K.; Yajima, T.; Kanai, T.; Inoue, N.; Iwao, Y.; Watanabe, M.; Ishii, H.; Hibi, T. Circulating autoantibodies against purified colonic mucin in ulcerative colitis. J. Gastroenterol. 2000, 35, 20-27.
59. Hayashi, T.; Ishida, T.; Motoya, S.; Itoh, F.; Takahashi, T.; Hinoda, Y.; Imai, K. Mucins and immune reactions to mucins in ulcerative colitis. Digestion 2001, 63, 28-31.
60. Klaamas, K.; Kurtenkov, O.; von Mensdorff-Pouilly, S.; Shljapnikova, L.; Miljukhina, L.; Brjalin, V.; Lipping, A. Impact of Helicobacter pylori infection on the humoral immune response to MUC1 peptide in patients with chronic gastric diseases and gastric cancer. Immunol. Investig. 2007, 36, 371-386.
61. Kotera, Y.; Fontenot, J.D.; Pecher, G.; Metzgar, R.S.; Finn, O.J. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res. 1994, 54, 2856-2860.
62. Richards, E.R.; Devine, P.L.; Quin, R.J.; Fontenot, J.D.; Ward, B.G.; McGuckin, M.A. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol. Immunother. 1998, 46, 245-252.
63. von Mensdorff-Pouilly, S.; Gourevitch, M.M.; Kenemans, P.; Verstraeten, A.A.; van Kamp, G.J.; Kok, A.; van Uffelen, K.; Snijdewint, F.G.; Paul, M.A.; Meijer, S. et al. An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1). Tumor Biol. 1998, 19, 186-195.
64. Treon, S.P.; Maimonis, P.; Bua, D.; Young, G.; Raje, N.; Mollick, J.; Chauhan, D.; Tai, Y.T.; Hideshima, T.; Shima, Y. et al. Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood 2000, 96, 3147-3153.
65. von Mensdorff-Pouilly, S.; Verstraeten, A.A.; Kenemans, P.; Snijdewint, F.G.; Kok, A.; Van Kamp, G.J.; Paul, M.A.; Van Diest, P.J.; Meijer, S.; Hilgers, J. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J. Clin. Oncol. 2000, 18, 574-583.
66. Davelaar, E.M.; van de Lande, J.; von Mensdorff-Pouilly, S.; Blankenstein, M.A.; Verheijen R.H.; Kenemans, P. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer. Tumor Biol. 2008, 29, 9-17.
67. Nakamura, H.; Hinoda, Y.; Nakagawa, N.; Makiguchi, Y.; Itoh, F.; Endo, T.; Imai, K. Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer. J. Gastroenterol. 1998, 33, 354-361.
68. Silk, A.W.; Schoen, R.E.; Potter, D.M.; Finn, O.J. Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer. Mol. Immunol. 2009, 47, 52-56.
69. Chapman, C.; Murray, A.; Chakrabarti, J.; Thorpe, A.; Woolston, C.; Sahin, U.; Barnes, A.; Robertson, J. Autoantibodies in breast cancer: Their use as an aid to early diagnosis. Ann. Oncol. 2007, 18, 868-873.
70. Lu, H.; Goodell, V.; Disis, M.L. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J. Proteome Res. 2008, 7, 1388-1394.
71. Piura, E.; Piura, B. Autoantibodies to tailor-made panels of tumor-associated antigens in breast carcinoma. J. Oncol. 2011, 2011, 982425.
72. Pandey, J.P.; Nietert, P.J.; von Mensdorff-Pouilly, S.; Klaamas, K.; Kurtenkov, O. Immunoglobulin allotypes influence antibody responses to mucin 1 in patients with gastric cancer. Cancer Res. 2008, 68, 4442-4446.
73. Pandey, J.P.; Nietert, P.J.; Klaamas, K.; Kurtenkov, O. A genetic variant of immunoglobulin gamma2 is strongly associated with immunity to mucin 1 in patients with breast cancer. Cancer Immunol. Immunother. 2009, 58, 2025-2029.
74. Hirasawa, Y.; Kohno, N.; Yokoyama, A.; Kondo, K.; Hiwada, K.; Miyake, M. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am. J. Respir. Crit. Care Med. 2000, 161, 589-594.
75. Hamanaka, Y.; Suehiro, Y.; Fukui, M.; Shikichi, K.; Imai, K.; Hinoda, Y. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int. J. Cancer 2003, 103, 97-100.
76. Kurtenkov, O.; Klaamas, K.; Mensdorff-Pouilly, S.; Miljukhina, L.; Shljapnikova, L.; Chuzmarov, V. Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: Relation to survival. Acta Oncol. 2007, 46, 316-323.
77. Oei, A.L.; Moreno, M.; Verheijen, R.H.; Sweep, F.C.; Thomas, C.M.; Massuger, L.F. von Mensdorff-Pouilly, S. Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer. Int. J. Cancer 2008, 123, 1848-1853.
78. Cramer, D.W.; Titus-Ernstoff, L.; McKolanis, J.R.; Welch, W.R.; Vitonis, A.F.; Berkowitz, R.S.; Finn, O.J. Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol. Biomark. Prev. 2005, 14, 1125-1131.
79. Cramer, D.W.; Vitonis, A.F.; Pinheiro, S.P.; McKolanis, J.R.; Fichorova, R.N.; Brown, K.E.; Hatchette, T.; Finn, O.J. Mumps and ovarian cancer: Modern interpretation of an historic association. Cancer Causes Control 2010, 21, 1193-1201.
80. Hermsen, B.B.; Verheijen, R.H.; Menko, F.H.; Gille, J.J.; van Uffelen, K.; Blankenstein, M.A.; Meijer, S.; van Diest, P.J.; Kenemans, P.; von Mensdorff-Pouilly, S. Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation. Eur. J. Cancer 2007, 43, 1556-1563.
81. von Mensdorff-Pouilly, S.; Petrakou, E.; Kenemans, P.; van Uffelen, K.; Verstraeten, A.A.; Snijdewint, F.G.; van Kamp, G.J.; Schol, D.J.; Reis, C.A.; Price, M.R. et al. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int. J. Cancer 2000, 86, 702-712.
82. Pedersen, J.W.; Blixt, O.; Bennett, E.P.; Tarp, M.A.; Dar, I.; Mandel, U.; Poulsen, S.S.; Pedersen, A.E.; Rasmussen, S.; Jess, P. et al. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int. J. Cancer 2011, 128, 1860-1871.
83. Drake, P.M.; Cho, W.; Li, B.; Prakobphol, A.; Johansen, E.; Anderson, N.L.; Regnier, F.E.; Gibson, B.W.; Fisher, S.J. Sweetening the pot: Adding glycosylation to the biomarker discovery equation. Clin. Chem. 2010, 56, 223-36.
84. Blixt, O.; Bueti, D.; Burford, B.; Allen, D.; Julien, S.; Hollingsworth, M.; Gammerman, A.; Fentiman, I.; Taylor-Papadimitriou, J.; Burchell, J.M. Auto antibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. Breast Cancer Res. 2011, 13, R25.
85. Burchell, J. Can auto-antibodies to aberrant glycoforms of MUC1 be used as prognostic and diagnostic markers? 11th Workshop on Mucins in Health and Disease, Cambridge, UK, 9-13 July 2011.
86. Karanikas, V.; Hwang, L.A.; Pearson, J.; Ong, C.S.; Apostolopoulos, V.; Vaughan, H.; Xing, P.X.; Jamieson, G.; Pietersz, G.; Tait, B. et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest. 1997, 100, 2783-2792.
87. Sandrin, M.S.; Vaughan, H.A.; Xing, P.X.; McKenzie, I.F. Natural human anti-Gal alpha(1,3)Gal antibodies react with human mucin peptides. Glycoconj. J. 1997, 14, 97-105.
88. von Mensdorff-Pouilly, S. Vaccine-induced antibody responses in patients with carcinoma. Expert Rev. Vaccines 2010, 9, 579-594.
89. Keilholz, U.; Weber, J.; Finke, J.H.; Gabrilovich, D.I.; Kast, W.M.; Disis, M.L.; Kirkwood, J.M.; Scheibenbogen, C.; Schlom, J.; Maino, V.C. et al. Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the Society for Biological Therapy. J. Immunother. 2002, 25, 97-138.
90. Schol, D.J.; Meulenbroek, M.F.; Snijdewint, F.G.; von Mensdorff-Pouilly, S.; Verstraeten, R.A.; Murakami, F.; Kenemans, P.; Hilgers, J. 'Epitope fingerprinting' using overlapping 20-mer peptides of the MUC1 tandem repeat sequence. Tumor Biol. 1998, 19, 35-45.
91. Petrarca, C.; Rughetti, A.; Rahimi, H.; Dagostini, F.; Turchi, V.; Ghetti, C.A.; Scambia, G.; Frati, L.; Nuti, M. Human antibodies against the polymorphic epithelial mucin in ovarian cancer patients recognise a novel sequence in the tandem repeat region. Eur. J. Cancer 1996, 32A, 2155-2163.
92. Henderikx, P.; Kandilogiannaki, M.; Petrarca, C.; von Mensdorff-Pouilly, S.; Hilgers, J.H.; Krambovitis, E.; Arends, J.W.; Hoogenboom, H.R. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma. Cancer Res. 1998, 58, 4324-4332.
93. Graves, C.R.; Robertson, J.F.; Murray, A.; Price, M.R.; Chapman, C.J. Malignancy-induced autoimmunity to MUC1: Initial antibody characterization. J. Pept. Res. 2005, 66, 357-363.
94. Ninkovic, T.; Kinarsky, L.; Engelmann, K.; Pisarev, V.; Sherman, S.; Finn, O.J.; Hanisch, F.G. Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes. Mol. Immunol. 2009, 47, 131-140.
95. von Mensdorff-Pouilly, S.; Kinarsky, L.; Engelmann, K.; Baldus, S.E.; Verheijen, R.H.; Hollingsworth, M.A.; Pisarev, V.; Sherman, S.; Hanisch, F.G. Sequence-variant repeats of MUC1 show higher conformational flexibility, are less densely O-glycosylated and induce differential B lymphocyte responses. Glycobiology 2005, 15, 735-746.
96. Vlad, A.M.; Muller, S.; Cudic, M.; Paulsen, H.; Otvos, L. Jr.; Hanisch, F.G.; Finn, O.J. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: Processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J. Exp. Med. 2002, 196, 1435-1446.
97. Hanisch, F.G.; Schwientek, T.; Von Bergwelt-Baildon, M.S.; Schultze, J.L.; Finn, O. O-Linked glycans control glycoprotein processing by antigen-presenting cells: A biochemical approach to the molecular aspects of MUC1 processing by dendritic cells. Eur. J. Immunol. 2003, 33, 3242-3254.
98. Ninkovic, T.; Hanisch, F.G. O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes. J. Immunol. 2007, 179, 2380-2388.
99. Wesseling, J.; Van der Valk, S.W.; Vos, H.L.; Sonnenberg, A.; Hilkens, J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J. Cell Biol. 1995, 129, 255-265.
100. Hilkens, J.; Ligtenberg, M.J.; Vos, H.L.; Litvinov, S.V. Cell membrane-associated mucins and their adhesion-modulating property. TIBS 1992, 17, 359-363.
101. Ligtenberg, M.J.L.; Buijs, F.; Vos, H.L.; Hilkens, J. Suppression of cellular aggregation by high levels of episialin. Cancer Res. 1992, 52, 2318-2324.
102. Kondo, K.; Kohno, N.; Yokoyama, A.; Hiwada, K. Decreased MUC1 expression induces E-Cadherin-mediated cell adhesion of breast cancer cell lines. Cancer Res. 1998, 58, 2014-2019.
103. McDermott, K.M.; Crocker, P.R.; Harris, A.; Burdick, M.D.; Hinoda, Y.; Hayashi, T.; Imai, K.; Hollingsworth, M.A. Overexpression of MUC1 reconfigures the binding properties of tumor cells. Int. J. Cancer 2001, 94, 783-791.
104. Regimbald, L.H.; Pilarski, L.M.; Longenecker, B.M.; Reddish, M.A.; Zimmermann, G.; Hugh, J.C. The breast mucin MUC1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res. 1996, 56, 4244-4249.
105. Kam, J.L.; Regimbald, L.H.; Hilgers, J.H.M.; Hoffman, P.; Krantz, M.J.; Longenecker, B.M.; Hugh, J.C. MUC1 synthetic peptide inhibition of intercellular adhesion molecule -1 and MUC1 binding requires six tandem repeats. Cancer Res. 1998, 58, 5577-5581.
106. Muller, W.A. Mechanisms of leukocyte transendothelial migration. Annu. Rev. Pathol. 2011, 6, 323-344.
107. Denda-Nagai, K.; Irimura, T. MUC1 in carcinoma-host interactions. Glycoconj. J. 2000, 17, 649-658.
108. Li, M.; Song, L.; Qin, X. Glycan changes: Cancer metastasis and anti-cancer vaccines. J. Biosci. 2010, 35, 665-673.
109. Sawada, T.; Ho, J.J.L.; Chung, Y.S.; Sowa, M.; Kim, J.Y.S. E selectin binding by pancreatic tumor cells is inhibited by cancer sera. Int. J. Cancer 1994, 57, 901-907.
110. Zhang, K.; Baeckstrom, D.; Brevinge, H.; Hansson, G.C. Secreted MUC1 mucins lacking their cytoplasmic part and carrying sialyl-Lewis a and x epitopes from a tumour cell line and sera of colon carcinoma patients can inhibit HL-60 leukocyte adhesion to E-selecting-expressing endothelial cells. J. Cell Biochem. 1996, 60, 538-549.
111. Swanson, B.J.; McDermott, K.M.; Singh, P.K.; Eggers, J.P.; Crocker, P.R.; Hollingsworth, M.A. MUC1 is a counter-receptor for myelin-associated glycoprotein (Siglec-4a) and their interaction contributes to adhesion in pancreatic cancer perineural invasion. Cancer Res. 2007, 67, 10222-10229.
112. Yu, L.G.; Andrews, N.; Zhao, Q.; McKean, D.; Williams, J.F.; Connor, L.J.; Gerasimenko, O.V.; Hilkens, J.; Hirabayashi, J.; Kasai, K. et al. Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. J. Biol. Chem. 2007, 282, 773-81.
113. Zhao, Q.; Barclay, M.; Hilkens, J.; Guo, X.; Barrow, H.; Rhodes, J.M.; Yu, L.G. Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. Mol. Cancer 2010, 9, 154.
114. Hayashi, T.; Takahashi, T.; Motoya, S.; Ishida, T.; Itoh, F.; Adachi, M.; Hinoda, Y.; Imai K. MUC1 mucin core protein binds to the domain 1 of ICAM-1. Digestion 2001, 63, 87-92.
115. Springer, T.A. Adhesion receptors of the immune system. Nature 1990, 346, 425-434.
116. Agrawal, B.; Krantz, M.J.; Reddish, M.A.; Longenecker, B. M. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat. Med. 1998, 4, 43-49.
117. Chan, A.K.; Lockhart, D.C.; Von Bernstorff, W.; Spanjaard, R.A.; Joo, H.-G.; Eberlein, T.J.; Goedegebuure, P.S. Soluble MUC1 secreted by human epithelial cancer cells mediate immune suppression by blocking T-cell activation. Int. J. Cancer 1999, 82, 721-726.
118. Snijdewint, F.G.M.; von Mensdorff-Pouilly, S.; Karuntu-Wanamarta, A.H.; Verstraeten, A.A.; van Zanten-Przybysz, I.; Hummel, P.; Nijman, H.W.; Kenemans, P.; Hilgers, J. Cellular and humoral responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls. Cancer Immunol. Immunother. 1999, 48, 47-55.
119. Nath, D.; Hartnell, A.; Happerfield, L.; Miles, D.W.; Burchell, J.; Taylor-Papadimitriou, J. Macrophage-tumour cell interactions: Identification of MUC1 on breast cancer cells as potential counter-receptors for the macrophage-restricted receptor, sialoadhesin. Immunology 1999, 98, 213-219.
120. Allavena, P.; Sica, A.; Garlanda, C.; Mantovani A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol. Rev. 2008, 222, 155-161.
121. Weiner, L.M.; Surana, R.; Wang, S. Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010, 10, 317-327.
122. Cartron, G.; Dacheux, L.; Salles, G.; Solal-Celigny, P.; Bardos, P.; Colombat, P.; Watier, H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99, 754-758.
123. Hubert, P.M.; Heitzmann, A.; Viel, S.; Nicolas, A.; Sastre-Garau, X.; Oppezzo, P.; Pritsch, O.; Osinaga, E.; Amigorena, S. Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy. Cancer Res. 2011, 71(15), 1-10.
124. Snijdewint, F.G.; von Mensdorff-Pouilly, S.; Karuntu-Wanamarta, A.H.; Verstraeten, A.A.; Livingston, P.O.; Hilgers, J.; Kenemans, P. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int. J. Cancer 2001, 93, 97-106.
125. Moreno, M.; Bontkes, H.J.; Scheper, R.J.; Kenemans, P.; Verheijen, R.H.; von Mensdorff-Pouilly, S. High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). Cancer Lett. 2007, 257, 47-55.
126. Moreno, M.; Mol, B.M.; Mensdorff-Pouilly, S.V.; Verheijen, R.H.; von Blomberg, B.M.; van den Eertwegh, A.J.; Scheper, R.J.; Bontkes, H.J. Toll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Cancer Lett. 2008, 272, 70-76.
127. Tang, C.K.; Katsara, M.; Apostolopoulos, V. Strategies used for MUC1 immunotherapy: Human clinical studies. Expert Rev. Vaccines 2008, 7, 963-975.
128. Scholl, S.; Squiban, P.; Bizouarne, N.; Baudin, M.; Acres, B.; von Mensdorff-Pouilly, S.; Shearer, M.; Beuzeboc, P.; Van Belle, S.; Uzielly, B. et al. Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2. J. Biomed. Biotechnol. 2003, 2003 194-201.
129. North, S.; Butts, C. Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers. Expert Rev. Vaccines 2005, 4, 249-257.
130. Loveland, B.E.; Zhao, A.; White, S.; Gan, H.; Hamilton, K.; Xing, P.X.; Pietersz, G.A.; Apostolopoulos, V.; Vaughan, H.; Karanikas, V. et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: A phase I trial in patients with adenocarcinoma. Clin. Cancer Res. 2006, 12, 869-877.
131. Ragupathi, G.; Gathuru, J.; Livingston, P.O. Antibody inducing polyvalent cancer vaccines. Cancer Treat. Res. 2005, 123, 157-180.
132. Cheever, M.A.; Higano, C.S. PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine. Clin. Cancer Res. 2011, 17, 3520-3526.
133. Bono, J.S.; Rha, S.Y.; Stephenson, J.; Schultes, B.C.; Monroe, P.; Eckhardt, G.S.; Hammond, L.A.; Whiteside, T.L.; Nicodemus, C.F.; Cermak, J.M. et al. Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: Evidence for the activation of humoral and cellular antitumor immunity. Ann. Oncol. 2004, 15, 1825-1833.
134. Hird, V.; Maraveyas, A.; Snook, D.; Dhokia, B.; Soutter, W.; Meares, C.; Stewart, J.; Mason, P.; Lambert, H.; Epenetos A. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br. J. Cancer 1993, 68, 403-406.
135. Courtenay-Luck, N.S.; Epenetos, A.A.; Sivalopenko, G.B.; Larche, M.; Barkans, J.R.; Ritter, MA. Development of anti-idiotypic antibodies against tumour antigens and autoantigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies. Lancet 1988, 332, 894-897.
136. Kosmas, C.; Epenetos, A.A.; Courtenay-Luck, N.S. Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer. Cancer 1994, 73, 3000-3010.
137. Verheijen, R.H.; Massuger, L.F.; Benigno, B.B.; Epenetos, A.A.; Lopes, A.; Soper, J.T.; Markowska, J.; Vyzula, R.; Jobling, T.; Stamp, G. et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J. Clin. Oncol. 2006, 24, 571-578.
138. Xing, P.; Michael, M.; Apostolopoulos, V.; Prenzoska, J.; Marshall, C.; Bishop, J.; McKenzie, I. Phase-I study of synthetic muc1 peptides in breast-cancer. Int. J. Oncol. 1995, 6, 1283-1289.
139. Reddish, M.; MacLean, G.D.; Koganty, R.R.; Kan-Mitchell, J.; Jones, V.; Mitchell, M.S.; Longenecker, B.M. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int. J. Cancer 1998, 76, 817-823.
140. Ramanathan, R.K.; Lee, K.M.; McKolanis, J.; Hitbold, E.; Schraut, W.; Moser, A.J.; Warnick, E.; Whiteside, T.; Osborne, J.; Kim, H. et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol. Immunother. 2005, 54, 254-264.
141. Karanikas, V.; Thynne, G.; Mitchell, P.; Ong, C.S.; Gunawardana, D.; Blum, R.; Pearson, J.; Lodding, J.; Pietersz, G.; Broadbent, R. et al. Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection. J. Immunother. 2001, 24, 172-183.
142. Apostolopoulos, V.; Pietersz, G.A.; Tsibanis, A.; Tsikkinis, A.; Drakaki, H.; Loveland, B.E.; Piddlesden, S.J.; Plebanski, M.; Pouniotis, D.S.; Alexis, M.N. et al. Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res. 2006, 8, R27.
143. Adluri, S.; Gilewski, T.; Zhang, S.; Ramnath, V.; Ragupathi, G.; Livingston, P. Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21. Br. J. Cancer 1999, 79, 1806-1812.
144. Gilewski, T.; Adluri, S.; Ragupathi, G.; Zhang, S.; Yao, T.J.; Panageas, K.; Moynahan, M.; Houghton, A.; Norton, L.; Livingston, P.O. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin. Cancer Res. 2000, 6, 1693-1701.
145. Gilewski, G.; Ragupathi, G.; Bhuta S.; Clausen, H.; Norton, L.; Houghton, A.; Livingston, P. Preliminary Data: Vaccination with glycosylated mucin 1 (MUC-1)-keyhole limpet hemocyanin (KLH) conjugate plus the immunological adjuvant QS21 in breast cancer patients. Proc. Am. Soc. Clin. Oncol. 2001, 20, Abstract 1082.
146. Sabbatini, P.J.; Ragupathi, G.; Hood, C.; Aghajanian, C.A.; Juretzka, M.; Iasonos, A.; Hensley, M.L.; Spassova, M.K.; Ouerfelli, O.; Spriggs, D.R. et al. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin. Cancer Res. 2007, 13, 4170-4177.
147. Ragupathi, G.; Liu, N.X.; Musselli, C.; Powell, S.; Lloyd, K.; Livingston, P.O. Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J. Immunol. 2005, 174, 5706-5712.
148. Slovin, S.F.; Ragupathi, G.; Fernandez, C.; Diani, M.; Jefferson, M.P.; Wilton, A.; Kelly, W.K.; Morris, M.; Solit, D.; Clausen, H. et al. A polyvalent vaccine for high-risk prostate patients: "Are more antigens better?" Cancer Immunol. Immunother. 2007, 56, 1921-1930.
149. Zhu, J.; Warren, J.D.; Danishefsky, S.J. Synthetic carbohydrate-based anticancer vaccines: The Memorial Sloan-Kettering experience. Expert Rev. Vaccines 2009, 8, 1399-1413.
150. Zhu, J.; Wan, Q.; Lee, D.; Yang, G.; Spassova, M.K.; Ouerfelli, O.; Ragupathi, G.; Damani, P.; Livingston, P.O.; Danishefsky, S.J. From synthesis to biologics: Preclinical data on a chemistry derived anticancer vaccine. J. Am. Chem. Soc. 2009, 131, 9298-9303.
151. Lee, D.; Danishefsky, S.J. "Biologic" level structures through chemistry: A total synthesis of a unimolecular pentavalent MUCI glycopeptide construct. Tetrahedron Lett. 2009, 50, 2167.
152. Kaiser, A.; Gaidzik, N.; Westerlind, U.; Kowalczyk, D.; Hobel, A.; Schmitt, E.; Kunz, H. A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: Induction of a strong and highly selective immune response. Angew Chem. Int. Ed. Engl. 2009, 48, 7551-7555.
153. Ingale, S.; Wolfert, M.A.; Buskas, T.; Boons, G.J. Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors. Chembiochem 2009, 10, 455-463.
154. Kaiser, A.; Gaidzik, N.; Becker, T.; Menge, C.; Groh, K.; Cai, H.; Li, Y.M.; Gerlitzki, B.; Schmitt, E.; Kunz, H. Fully synthetic vaccines consisting of tumor-associated MUC1 glycopeptides and a lipopeptide ligand of the Toll-like receptor 2. Angew Chem. Int. Ed. Engl. 2010, 49, 3688-3692.
155. Hoffmann-Röder, A.; Kaiser, A.; Wagner, S.; Gaidzik, N.; Kowalczyk, D.; Westerlind, U.; Gerlitzki B.; Schmitt, E.; Kunz, H. Synthetic antitumor vaccines from tetanus toxoid conjugates of MUC1 glycopeptides with the Thomsen-Friedenreich antigen and a fluorine-substituted analogue. Angew Chem. Int. Ed. Engl. 2010, 49, 8498-8503.
156. Wilkinson, B.L.; Day, S.; Malins, L.R.; Apostolopoulos, V.; Payne, R.J. Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer. Angew Chem. Int. Ed. Engl. 2011, 50, 1635-1639.
157. Cai, H.; Huang, Z.H.; Shi, L.; Zhao, Y.F.; Kunz, H.; Li, Y.M. Towards a Fully Synthetic MUC1-Based Anticancer Vaccine: Efficient Conjugation of Glycopeptides with Mono-, Di-, and Tetravalent Lipopeptides Using Click Chemistry. Chemistry 2011, 17, 6396-6406.
158. Reilly, R.T.; Emens, L.A.; Jaffee, E.M. Humoral and cellular immune responses: Independent forces or collaborators in the fight against cancer? Curr. Opin. Investig. Drugs 2001, 2, 133-135.
159. Smyth, M.J.; Dunn, G.P.; Schreiber, R.D. Cancer immunosurveillance and immunoediting: The roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 2006, 90, 1-50.
160. Koebel, C.M.; Vermi, W.; Swann, J.B.; Zerafa, N.; Rodig, S.J.; Old, L.J.; Smyth, M.J.; Schreiber, R.D. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450, 903-907.
161. Pantel, K.; Brakenhoff, R.H. Dissecting the metastatic cascade. Nat. Rev. Cancer 2004, 4, 448-456.
162. Slade, M.J.; Singh, A.; Smith, B.M.; Tripuraneni, G.; Hall, E.; Peckitt, C.; Fox, S.; Graham, H.; Lüchtenborg, M.; Sinnett, H.D. et al. Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: Results at 4 years. Int. J. Cancer 2005, 114, 94-100.
163. Livingston, P.O.; Ragupathi, G.; Musselli, C. Autoimmune and antitumor consequences of antibodies against antigens shared by normal and malignant tissues. J. Clin. Immunol. 2000, 20, 85-93.
164. Farkas, A.M.; Finn, O.J. Vaccines based on abnormal self-antigens as tumor-associated antigens: Immune regulation. Semin. Immunol. 2010, 22, 125-131.
165. Finke, L.H.; Wentworth, K.; Blumenstein, B.; Rudolph, N.S.; Levitsky, H.; Hoos, A. Lessons from randomized phase III studies with active cancer immunotherapies-Outcomes from the 2006 Meeting of the Cancer Vaccine Consortium (CVC). Vaccine 2007, 25, B97-B109.
166. Hoos, A.; Parmiani, G.; Hege, K.; Sznol, M.; Loibner, H.; Eggermont, A.; Urba, W.; Blumenstein, B.; Sacks, N.; Keilholz, U. et al. Cancer Vaccine Clinical Trial Working Group. A clinical development paradigm for cancer vaccines and related biologics. J. Immunother. 2007, 30, 1-15.